Related references
Note: Only part of the references are listed.Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Martin Bossart et al.
CELL METABOLISM (2022)
The therapeutic potential of GLP-1 receptor biased agonism
Ben Jones
BRITISH JOURNAL OF PHARMACOLOGY (2022)
Preclinical evaluation of a protracted GLP-1/glucagon receptor co-agonist: Translational difficulties and pitfalls
Lotte Simonsen et al.
PLOS ONE (2022)
The mediation by GLP-1 receptors of glucagon-induced insulin secretion revisited in GLP-1 receptor knockout mice
Bo Ahren et al.
PEPTIDES (2021)
The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang et al.
CELL METABOLISM (2021)
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial
Thomas A. Wadden et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Once-Weekly Semaglutide in Adults with Overweight or Obesity
John P. H. Wilding et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial
Domenica Rubino et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
Julie R. Lundgren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Novel GIP/GLP-1/Glucagon Receptor Agonist LY3437943: A First-in-Human Dose Study in Healthy Subjects
Shweta Urva et al.
DIABETES (2021)
The Novel GIP, GLP-1, and Glucagon Triple Receptor Agonist LY3437943 Exhibits Robust Efficacy in Preclinical Models of Obesity and Diabetes
Tamer Coskun et al.
DIABETES (2021)
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist-Induced Nausea and Emesis in Preclinical Models
Tito Borner et al.
DIABETES (2021)
Effects of Cotadutide on Metabolic and Hepatic Parameters in Adults With Overweight or Obesity and Type 2 Diabetes: A 54-Week Randomized Phase 2b Study
Rajaa Nahra et al.
DIABETES CARE (2021)
Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling
Ville Karhunen et al.
DIABETOLOGIA (2021)
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frias et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Sequencing of 640,000 exomes identifies GPR75 variants associated with protection from obesity
Parsa Akbari et al.
SCIENCE (2021)
Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
Juan P. Frias et al.
LANCET DIABETES & ENDOCRINOLOGY (2021)
GIPR antagonist antibodies conjugated to GLP-1 peptide are bispecific molecules that decrease weight in obese mice and monkeys
Shu-Chen Lu et al.
CELL REPORTS MEDICINE (2021)
Efficacy, Safety, and Mechanistic Insights of Cotadutide, a Dual Receptor Glucagon-Like Peptide-1 and Glucagon Agonist
Victoria E. R. Parker et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates
Patrick J. Knerr et al.
PEPTIDES (2020)
Dual glucagon-like peptide-1 receptor/glucagon receptor agonist SAR425899 improves beta-cell function in type 2 diabetes
Roberto Visentin et al.
DIABETES OBESITY & METABOLISM (2020)
An overview of GLP-1 agonists and recent cardiovascular outcomes trials
Kelsey H. Sheahan et al.
POSTGRADUATE MEDICAL JOURNAL (2020)
GIP as a Therapeutic Target in Diabetes and Obesity: Insight From Incretin Co-agonists
Jens Juul Holst et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2020)
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams et al.
DIABETES THERAPY (2020)
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Francis S. Willard et al.
JCI INSIGHT (2020)
How May GIP Enhance the Therapeutic Efficacy of GLP-1?
Ricardo J. Samms et al.
TRENDS IN ENDOCRINOLOGY AND METABOLISM (2020)
Chronic glucose-dependent insulinotropic polypeptide receptor (GIPR) agonism desensitizes adipocyte GIPR activity mimicking functional GIPR antagonism
Elizabeth A. Killion et al.
NATURE COMMUNICATIONS (2020)
Receptor occupancy of dual glucagon-like peptide 1/glucagon receptor agonist SAR425899 in individuals with type 2 diabetes
Olof Eriksson et al.
SCIENTIFIC REPORTS (2020)
Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis
Marie Winther-Sorensen et al.
MOLECULAR METABOLISM (2020)
Semaglutide lowers body weight in rodents via distributed neural pathways
Sanaz Gabery et al.
JCI INSIGHT (2020)
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials
Joachim Tillner et al.
DIABETES OBESITY & METABOLISM (2019)
Designing Poly-agonists for Treatment of Metabolic Diseases: Challenges and Opportunities
Jonas Petersen et al.
DRUGS (2019)
Glucagon Regulation of Energy Expenditure
Maximilian Kleinert et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism
Piotr A. Mroz et al.
MOLECULAR METABOLISM (2019)
Optimization of peptide-based polyagonists for treatment of diabetes and obesity
Patrick J. Knerr et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
Glucagon Receptor Signaling Regulates Energy Metabolism via Hepatic Farnesoid X Receptor and Fibroblast Growth Factor 21
Teayoun Kim et al.
DIABETES (2018)
Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials
Bo Ahren et al.
DIABETES OBESITY & METABOLISM (2018)
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Megan E. Capozzi et al.
ENDOCRINE REVIEWS (2018)
Hemodynamic Effects of Glucagon: A Literature Review
Kasper Meidahl Petersen et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2018)
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study
Philip Ambery et al.
LANCET (2018)
Combination Therapies for Obesity
Michael Camilleri et al.
METABOLIC SYNDROME AND RELATED DISORDERS (2018)
Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
Patrick M. O'Neil et al.
LANCET (2018)
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists
T. D. Mueller et al.
PHARMACOLOGICAL REVIEWS (2018)
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial
Juan Pablo Frias et al.
LANCET (2018)
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models
Elizabeth A. Killion et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept
Tamer Coskun et al.
MOLECULAR METABOLISM (2018)
A novel GIP analogue, ZP4165, enhances glucagon-like peptide-1-induced body weight loss and improves glycaemic control in rodents
Pia K. Norregaard et al.
DIABETES OBESITY & METABOLISM (2018)
Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical trials
Karolin Bettge et al.
DIABETES OBESITY & METABOLISM (2017)
GLP-1/glucagon receptor co-agonism for treatment of obesity
Miguel A. Sanchez-Garrido et al.
DIABETOLOGIA (2017)
Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
John Blundell et al.
DIABETES OBESITY & METABOLISM (2017)
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes
Juan Pablo Frias et al.
CELL METABOLISM (2017)
Liraglutide for weight management: a critical review of the evidence
A. Mehta et al.
OBESITY SCIENCE & PRACTICE (2017)
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans
V. Salem et al.
DIABETES OBESITY & METABOLISM (2016)
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity
Matthias H. Tschoep et al.
CELL METABOLISM (2016)
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates
S. J. Henderson et al.
DIABETES OBESITY & METABOLISM (2016)
Reappraisal of GIP Pharmacology for Metabolic Diseases
Brian Finan et al.
TRENDS IN MOLECULAR MEDICINE (2016)
The New Era of Drug Therapy for Obesity: The Evidence and the Expectations
Ben J. Jones et al.
DRUGS (2015)
Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide
Jesper Lau et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents
Brian Finan et al.
NATURE MEDICINE (2015)
GLP-1 and Glucose Tolerance After Sleeve Gastrectomy in Morbidly Obese Subjects With Type 2 Diabetes
Amanda Jimenez et al.
DIABETES (2014)
Cardiovascular and hemodynamic effects of glucagon-like peptide-1
Adam G. Goodwill et al.
REVIEWS IN ENDOCRINE & METABOLIC DISORDERS (2014)
Unimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Brian Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Peptide lipidation stabilizes structure to enhance biological function
Brian P. Ward et al.
MOLECULAR METABOLISM (2013)
Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents
Jonathan W. Day et al.
BIOPOLYMERS (2012)
Chronic exposure to GLP-IR agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo
LL Baggio et al.
DIABETES (2004)
Glucose-dependent insulinotropic polypeptide receptor null mice exhibit compensatory changes in the enteroinsular axis
N Pamir et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2003)
Inhibition of gastric inhibitory polypeptide signaling prevents obesity
K Miyawaki et al.
NATURE MEDICINE (2002)
Share Paper
